GlassScriptPhysician profile
Michael J Potes
NPI 1770074114
$3,290.83
in general payments reported to CMS, 2019-2025
26 companies · $77.38 in 2025
The $77.38 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.36 · 2020: $355 · 2021: $390 · 2022: $313 · 2023: $1,390 · 2024: $673 · 2025: $77.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.09 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $492.45 | 2022-2024 | |
| Janssen Biotech, INC. | $361.34 | 2022-2024 | Stelara, Tremfya, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $251.82 | 2022-2024 | Dupixent |
| Gilead Sciences, INC. | $236.15 | 2020-2023 | Epclusa |
| Ardelyx, INC. | $185.71 | 2023-2024 | Ibsrela |
| Qol Medical, LLC | $156.65 | 2022-2023 | Sucraid |
| Novo Nordisk INC | $140.96 | 2021-2025 | Wegovy |
| Medtronic, INC. | $128.91 | 2023 | Gi Genius |
| Amgen INC. | $124.74 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $117.80 | 2021 | |
| Vifor Pharma, INC. | $116.34 | 2020 | |
| Intercept Pharmaceuticals, INC. | $115.12 | 2022 | |
| Janssen Scientific Affairs, LLC | $113.52 | 2020 | |
| Evoke Pharma, INC. | $103.45 | 2023 | Gimoti |
| Takeda Pharmaceuticals U.S.A., INC. | $100.36 | 2022-2025 | Entyvio, Gattex |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $95.13 | 2021-2023 | Dificid |
| Janssen Pharmaceuticals, INC | $91.36 | 2019 | |
| Exact Sciences Corporation | $86.31 | 2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $80.04 | 2023-2024 | Exalt Model D |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.83 | 2021-2023 | Xifaxan |
| Sandoz INC. | $42.43 | 2023-2024 | Hyrimoz |
| Genzyme Corporation | $29.90 | 2025 | |
| Ironwood Pharmaceuticals, INC | $23.02 | 2023 | Linzess |
| Organon LLC | $17.84 | 2023 | Hadlima |
| Nestle Healthcare Nutrition INC. | $17.65 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Potes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.